Grey Matters!
Finding Grey Literature

Sarah McGill, BSc, MLIS
Amanda Hodgson, MLIS

March 12, 2010
**CADTH Workshop: Grey Matters!**

*Finding Grey Literature for Health Topics*

*March 12, 2010 - Toronto, ON*

**REGISTER NOW!**

---

The Canadian Agency for Drugs and Technologies in Health (CADTH) is a national body that provides Canada’s federal, provincial, and territorial health care decision makers with credible, impartial advice and evidence-based information about the effectiveness and efficiency of drugs and other health technologies.

**What’s New**

- CADTH Interim Organizational Assignments
  - February 23, 2010
- 2010 CADTH Symposium Preliminary Program
  - Updated – Register Now
  - February 17, 2010

<table>
<thead>
<tr>
<th>Health Technology Assessment</th>
<th>Common Drug Review</th>
<th>Canadian Optimal Medication Prescribing &amp; Utilization Service</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective, comprehensive, factual assessments of the clinical effectiveness, cost effectiveness, and broader impact of drugs, health technologies, and health systems.</td>
<td>Objective, rigorous reviews of the clinical and cost effectiveness of drugs. Formulary listing recommendations for Canada’s publicly funded drug plans.</td>
<td>Identification and promotion of evidence-based optimal drug therapy.</td>
</tr>
</tbody>
</table>

**In Memoriam:** Dr. Jill M. Sanders

---

[Webpage Screenshot](#)
Introduction - Outline

• Objective of the presentation is to discuss:
• Definition of grey literature
• Benefits and challenges of searching for grey literature
• How to construct and execute a grey literature search
• Present the CADTH Grey Matters Checklist to assist you in your searches

* Question and Answer session at the end of the presentation
What is Grey Literature?

Grey

In-house

Fugitive

Gray

Unpublished

Deep Web
What is Grey Literature?

International Conference on Grey Literature. "Information produced on all levels of government, academics, business and industry in electronic and print formats not controlled by commercial publishing i.e. where publishing is not the primary activity of the producing body." (Luxembourg, 1997 - Expanded in New York, 2004) [http://www.greynet.org/greynethome.html](http://www.greynet.org/greynethome.html)

What is Grey Literature?

1. How are grey literature definitions changing...or going grey?

2. What is grey literature searching?

3. Remember, the search is greater than the definition!
Benefits of Grey Literature

• Current

• Often free

• Relevant and unique

• Information on non-mainstream topics or aspects

• Aids in identifying terms for search strategies
Publication Bias

Necessary for certain types of research, like systematic reviews ---

“…. published trials tend to be larger and show an overall greater treatment effect than grey trials. This has important implications for reviewers who need to ensure they identify grey trials, in order to minimise the risk of introducing bias into their review.”

“Unpublished trials contribute about 20% of the weight in individual meta-analysis.”

Challenges of Grey Literature

- Hard to find
- Many documents aren’t web-published
- Older reports may not be archived online
- Format & citation information may be inconsistent
- May not be indexed or have a search interface
- Volume of material can be overwhelming and time-consuming
- Quality of evidence varies…
Quality of Evidence Hierarchy

- Systematic Reviews, Meta-Analyses, Health Technology Assessments
- Randomized Controlled Trials
- Clinical Controlled Trials
- Observational Studies (Cohort and Case-Control Studies)
- Case Studies, Expert Opinion
Starting your Grey Literature Search

What is the purpose of the search?

What is the resulting report or information product?

What are your search parameters?

**Topic, limits on date, geography, publication types**
CADTH Systematic Search Approach

1. Topic definition (PICO) and search terms

2. Comprehensive literature search

(a) Database search for commercially published literature (e.g. Ovid databases, PubMed)

(b) “Grey Literature” component

- Often started at Step 1 to unearth search terms
- CADTH Grey Literature Checklists
1. Topic Definition

**PICO Model:**

- **Population** (Patient, Population, Problem)
- **Intervention**
- **Comparator**
- **Outcome**

*Describe each & find synonyms*
PICO Example

Question: what is the effectiveness of LABA plus corticosteroid inhalers compared to separate medication treatments for asthma?

P: Asthma patients

I: LABA plus inhaled corticosteroids (ICS) administered by inhaler

C: LABA alone, ICS alone, or other asthma medications/inhalers

O: Better control of asthma symptoms; reduced airflow obstruction
2. CADTH Grey Literature Checklist Online

Grey Matters:

a practical tool for evidence-based searching

http://www.cadth.ca/
The Canadian Agency for Drugs and Technologies in Health (CADTH) is a national body that provides Canada’s federal, provincial and territorial health care decision makers with credible, impartial advice and evidence-based information about the effectiveness and efficiency of drugs and other health technologies.
Drug and Device Regulatory Approvals

Canada

Conseil du médicament Québec
http://www.cdm.gouv.qc.ca/site/index.php?accueil
Using Google Advanced Search, type “www.cdm.gouv.qc.ca” in the domain box and type the drug name in the search box. For English publications, click on the “English Section” link in the left menu.
[Languages: French, English]

Health Canada: Summary Basis of Decision (SBD)
http://hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/index_e.html

Health Canada: Notice of Compliance Search
This is a drug approval database.
[Languages: English, French]

Medical Devices Active License Listing
http://www.mdall.ca
Select “Active License Search.”
[Languages: English, French]
Review: Tips for Saving Time

1. Do you need a few key items or a comprehensive search?

2. Scope out major systematic reviews (e.g. Cochrane reviews) and HTAs first
   - Higher quality of evidence & reviews the literature
   - Search strategy and keyword ideas for database search

3. Have a well-developed strategy in advance
   - Having a PICO & synonyms reduces backtracking
   - Use a checklist for tracking sources

4. Corollary: don’t spend too much time tracking!
   - Record URL & minimal details to fully cite later
Grey Literature Categories

Health Technology Assessment (HTA) agencies
Health Economics
Clinical Practice Guidelines
Drug/Devices Approval
Advisories/Warnings
Drug Class Reviews
Clinical Trials
Databases
Statistics
Open Access Journals
Additional Grey Literature Types and Sources
Health Technology Assessments (HTAs)

Highest quality evidence comes from:

• Systematic reviews (SR)
• Meta-analyses (MA)
• Health technology assessments (HTA)
Systematic Review

Review of studies in which evidence has been systematically searched for, studied, assessed, and summarised according to predetermined criteria.

Definitions based on NLM, Cochrane Glossary, INAHTA, CADTH definitions.
Meta-analysis

Use of *statistical techniques for combining results from different studies to obtain a quantitative estimate of the overall effect of a particular intervention, potentially producing a stronger conclusion than any individual study*
Health Technology Assessment

Multidisciplinary and systematic policy analysis, that studies the clinical, social, ethical, and economic implications of a drug, medical system, or health technology.

Primary purpose is to inform health policy and clinical practice decision makers.
HTA Highlights

Canadian:

Canadian Agency for Drugs and Technologies in Health (CADTH) [http://www.cadth.ca](http://www.cadth.ca)

Agence d’évaluation des technologies et des modes d’intervention en santé (AETMIS) [http://www.aetmis.gouv.qc.ca/](http://www.aetmis.gouv.qc.ca/)

International:


National Coordinating Centre for Health Technology Assessment & their NIHR Health Technology Assessment Program [http://www.hta.ac.uk/](http://www.hta.ac.uk/)
Health Technology Assessment

The Health Technology Assessment Program (HTA) provides high-quality information about the clinical effectiveness, cost-effectiveness, and broader impact of drugs, medical technologies, and health systems.

We tailor our evidence-based reports and information products to support and inform those who make decisions about health policy and purchasing, service management, and clinical practice.

Search Canadian HTA websites

This search tool includes Canadian health technology assessment (HTA) agencies and organizations that are involved in systematic reviews, meta-analyses, and health economics. Access the Canadian sites that CADTH has included as part of this search tool.

Search Canadian HTA websites
Publications - Complete list

List of scientific publications from the Agency


2009

Sentinel Lymph Node Biopsy in Breast Cancer Treatment: Technical Aspects
- 2009_10_res_en.pdf | English summary | 224.1 KB
- ETMIS2009_Vol5_No10.pdf | French report | 2 MB
- 2009_10_res_fr.pdf | French summary | 459.8 KB

Curative Treatment for Esophageal Cancer: Systematic Review of Neoadjuvant Therapy and Chemoradiotherapy Alone
- 2009_09_res_en.pdf | English summary | 340.4 KB
- ETMIS2009_Vol5_No9.pdf | French report | 1.9 MB
- 2009_09_res_fr.pdf | French summary | 348.9 KB
Search Vortal content

The HTAi Vortal continues to develop a new federated search application using Google that searches across all public-access web sites currently listed in the HTAi Vortal.

Use the Google search tips to refine your search. Your results list will appear as Google pages.

Questions/Feedback? Email allgoode67@verizon.net

Try out the Vortal custom search box to search multiple HTA and related web sites:

Google Custom Search [Search]
Welcome

The HTA programme is part of the National Institute for Health Research (NIHR). It produces independent research information about the effectiveness, costs and broader impact of healthcare treatments and tests for those who plan, provide or receive care in the NHS.

For details about the new NIHR/MRC joint strategy for translational research and the new opportunities for research that this presents visit our new opportunities zone.

Our research

Browse HTA research

Browse published HTA research, research in progress and investigate HTA research priorities

Research for policy makers

Find out about HTA research for NICE and other policy customers

Working with us

Looking for funding?

Find out about current HTA funding opportunities and how to apply.

Make a research suggestion

Find out how to go about suggesting a research topic for the HTA programme
Health Economics

*Focus is on choices, value judgements with regard to health care decision making*

- Direct/indirect costs
- Statistics, incidence/prevalence
- Socioeconomic
- Quality of life

*Economic evaluations*
  - cost-effectiveness
  - cost-minimization
  - cost-benefit
  - cost-utility
Health Economics

Highlights

Centre for Health Economics and Policy Analysis (CHEPA)
http://www.chepa.org

EURONHEED (European Network of Health Economic Evaluation Databases)
http://infodoc.inserm.fr/euronheed/Publication.nsf
CHEPA Faculty members produce an average of 100 publications per year, including books, peer-reviewed articles, editorials and government reports. Research conducted by CHEPA members and staff can be found in a range of journals and other publications that deal with health economics, health policy and health treatments and care.

A comprehensive database of all publications by CHEPA faculty from 1992 to April 2009 is available. To search this database, click here.

Recent Publications


Grignon M. An empirical investigation of heterogeneity in time preferences and smoking behaviors. 2009 October; 38(5) 739-751.

Hoffman SJ, Lavis JN, Bennett S. The use of
Working Papers

Featuring the research of faculty, associates, and staff of the Centre, this series provides a means to circulate polished, but not yet published, reports of compiled research. CHEPA Working Papers are available as pdfs.

To submit a paper to the series please complete the submission review form.

10-01: Mentzakis E, Stefanowska P, Hurley J. A Discrete Choice Experiment Investigating Preferences for Funding Drugs Used to Treat Orphan Diseases Available in PDF


09-02: Giacomini M. Theory Based Medicine and the Role of Evidence: Why the Emperor Needs New Clothes, Again Available as a PDF
The EURONHEED Project has been initiated by the Collège des Économistes de la Santé (CES), the French Health Economists Association, which will act as overall co-ordinator and six other European centres are partners of the Project:

CRD - University of York (UK),
FGG - Universitäet Hannover (GE),
IBMG - Erasmus University in Rotterdam (NL),
CESAV - Istituto Ricerche Farmacologici M.Negri (IT),
Dpt Economics - Universidad de la Rioja (SP),
SHECAB - Stockholm Health Economics (SW)

Funding for 3 years has been obtained in 2002 through successful application to the European Commission under the programme Quality of Life and Management of Living Resources (contract QLG7-CT2002-02379). The project was launched in February 2003.

The aim of the project is to develop a European Network of Health Economic Evaluation Databases.

This network will be built on the foundations of two established databases UK's NHS Economic Evaluation Database (NHS EED) and the French Connaissances et Décision en Économie de la Santé (CODECS) database.

The EURONHEED portal, gathering the 7 EURONEED databases is open to the public since the September 2005.
Number of documents found :3

<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom</td>
<td>Gescnick</td>
<td>2005</td>
</tr>
<tr>
<td>[Replication or Save Conflict]</td>
<td>K</td>
<td></td>
</tr>
<tr>
<td>Methylphenidate in children with hyperactivity: review and cost-utility analysis</td>
<td>Gilmore</td>
<td>2001</td>
</tr>
</tbody>
</table>

**Note:**
- The table lists three documents found regarding health economics, with one marked as incorrect due to a reason indicated as ‘K’.
Title
Methylphenidate in children with hyperactivity: review and cost-utility analysis

Authors
Gimore A; Milne R

References
20010201358

Source

Publication language
GB

Keywords (from the authors)
-

Keywords (MESH)
Subject indexing assigned by NLM:
Attention-Deficit-Disorder-with-Hyperactivity/dt (drug-therapy);
Attention-Deficit-Disorder-with-Hyperactivity/ec (economics);
Child; Costs-and-Cost-Analysis; Great-Britain; Human;
Methylphenidate/ec; (economics);
Methylphenidate/tu (therapeutic-use); Quality-Adjusted-Life-Years;
Randomized-Controlled-Trials; Sensitivity-and-Specificity;
Sympathomimetics/ec (economics); Sympathomimetics/tu (therapeutic-use)

Health technology
The use of methylphenidate for the treatment of children with hyperkinetic disorders, as defined using the ICD-10 criteria.
Clinical Practice Guidelines

A search for clinical practice guidelines may extend to association websites or organizations dedicated to a particular disease or patient group, depending on the requirements of the search.

• Guidelines
• Protocols
• Position statements
• Patient information sheets and resources
Clinical Practice Guidelines

Highlights

National Guideline Clearinghouse

http://www.guideline.gov

NHS National Institute for Clinical Excellence (NICE)

http://www.nice.org.uk
NGC Search Results

Your search criteria:

**Keyword:** "rheumatoid arthritis" AND (abatacept* OR ocrecia*)

Your search found 4 related guidelines, which are listed below by relevance. Use the "Limit Search" button to sort by publication date.

To view a guideline summary, click on a title below.

- Limit Search
- Select All
- Add to My Collection

**Items 1 to 4**

**Title**

- **Clinical practice guideline for the management of rheumatoid arthritis in Spain.** Advanced Research Techniques in the Health Sector. 2003. NGC:000000

Other Guidelines from this Developer
Brief Summary

GUIDELINE TITLE
Abatacept for the treatment of rheumatoid arthritis.

BIBLIOGRAPHIC SOURCE(S)

GUIDELINE STATUS
This is the current release of the guideline.

BRIEF SUMMARY CONTENT

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS
Abatacept is not recommended (within its marketing authorisation) for the treatment of people with rheumatoid arthritis.

Patients currently receiving abatacept for the treatment of rheumatoid arthritis should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

CLINICAL ALGORITHM(S)
Musculoskeletal

Click on the links below to see details of all the clinical guidelines, published or in development, in this topic area.

- **Completed guidelines**
  - Rheumatoid arthritis

- **Guidelines in development**
  - None

- **Completed appraisals**
  - Rheumatoid arthritis (refractory) - abatacept
  - Rheumatoid arthritis (refractory) - rituximab
  - Rheumatoid arthritis - adalimumab, etanercept and infliximab
  - Rheumatoid arthritis - certolizumab pegol
Drug and Devices Approvals

Regulatory approvals must be granted by government bodies for drugs and health devices. Information on the expansion of patient groups for previously approved drugs or withdrawals of medicines/devices from the market are often available.
Drug and Devices Approvals

Highlights

Medical Devices Active License Listing (Canada)

http://www.mdall.ca

European Medicines Agency

http://www.ema.europa.eu/
EPARs for authorised medicinal products for human use

Prezista

European Public Assessment Report

Revision 12 - Published 05/11/09

Glossary

<table>
<thead>
<tr>
<th>Product Information*</th>
</tr>
</thead>
<tbody>
<tr>
<td>23/10/2009 Prezista-H-C-707-II-27</td>
</tr>
</tbody>
</table>

(*) This document includes:
- Annex I - Summary of product characteristics
- Annex IIa - Manufacturing Authorisation holder responsible for Batch Release
- Annex IIb - Conditions of the Marketing Authorisation
- Annex IIIa - Labelling
- Annex IIIb - Package Leaflet

Please note that the size of the above document can exceed 50 pages. You are therefore advised to be selective about which sections or pages you wish to print.
Advisories/Warnings

Medical advisories and warnings are reported by governments internationally.

- Adverse effect/events
- Safety concerns (devices and medical procedures)
- Withdrawals from the market
Advisories/Warnings

Highlights

**MedEffect. Health Canada**

http://www.hc-sc.gc.ca/dhp-mps/medeff/index_e.html

**Medwatch. U.S. Food and Drug Administration**

http://www.fda.gov/Safety/MedWatch/default.htm
Advisories/Warnings - MedEffect

MedEffect Canada

MedEffect Canada provides consumers, patients, and health professionals with easy access to:

- Report an adverse reaction or side effect;
- Obtain new safety information on drugs and other health products; and
- Learn and better understand the importance of reporting side effects.

Latest Advisories, Warnings and Recalls

- Foreign Product Alert - Tian Yang Xu Huo Oral Ulcer Capsule (2010-03-01)
- Foreign Product Alert - STROQ Emperor Capsules [2010-03-01]
- Foreign Product Alert - 55 products sold through Bodybuilding.com [2010-03-01]
Drugs Class Reviews

Highlights

Drug Effectiveness Review Project (DERP), Oregon Health & Science University

http://www.ohsu.edu/drugeffectiveness/reports/index.cfm

U.S. Department of Veterans Affairs, Drug Class Reviews

http://www.pbm.va.gov/PMB/reviews.htm
Clinical Trials (Ongoing)

Valuable information on the safety and efficacy of new drugs and therapies as well as new uses for known treatments

Information on studies that may not be published yet

Tip: Check the product manufacturer’s website for trial lists
Clinical Trials (Ongoing)

Highlights

ClinicalTrials.gov (U.S. National Institutes of Health)

http://clinicaltrials.gov/

Current Controlled Trials

http://www.controlled-trials.com/
<table>
<thead>
<tr>
<th>Rank</th>
<th>Status</th>
<th>Study</th>
</tr>
</thead>
</table>
| 1    | Active, not recruiting    | A Pediatric Trial to Provide Dose Recommendation of TMC114/Rtv in HIV-1 Infected Children and Adolescents  
  Conditions: HIV-1, HIV Infections  
  Interventions: Drug: TMC114/rtv Part I and Part II (20-50kg), Drug: TMC114/rtv Part I and Part II (20-50kg),  
  Drug: TMC114/rtv Part III (Adult dose>50kg)  
  Group: Child  
  Phase: Phase II  
  NCT ID: NCT00355524 |
| 2    | Active, not recruiting    | TMC114-TIDP29-C228 - A Safety Study to Evaluate the Antiviral Activity of Darunavir (DRV) in Combination With Ritonavir (Rtv) in HIV 1 Infected Children From 3 Years to Below 6 Years of Age  
  Condition: HIV Infections  
  Interventions: Drug: liquid ritonavir; Drug: Darunavir tablets; Drug: Darunavir suspension  
  Group: Child  
  Phase: Phase II  
  NCT ID: NCT00919854 |
Databases

- Excellent place to find key sources FAST
- Retrieve grey literature in addition to traditional commercially published literature

**NHS CRD**

Centre for Reviews & Dissemination, University of York, UK

[http://www.crd.york.ac.uk/crdweb/](http://www.crd.york.ac.uk/crdweb/)

**Cochrane Library (free full text in NB, NS, NU, SK, YK, NWT)**


**TRIP Database** [http://www.tripdatabase.com/](http://www.tripdatabase.com/)
CRD Databases

**DARE** contains 15,000 abstracts of systematic reviews including over 6,000 quality assessed reviews and details of all Cochrane reviews and protocols.

**NHS EED** contains 24,000 abstracts of health economics papers including over 7,000 quality assessed economic evaluations.

**DARE** and **NHS EED** include details of abstracts in the process of being written and these can be 'fast-tracked' on request.

**HTA** brings together details of over 8,000 completed and ongoing health technology assessments from around the world.

Sign up for weekly email alerts of new content

Centre for Reviews & Dissemination, University of York, York, UK, Y010 5DD
Tel: +44 (0)1904 321040, Fax: +44 (0)1904 321041, E-mail: crd-info@york.ac.uk

Disclaimer
### Search Results

Show Results in:
- Cochrane Reviews [23]
- Other Reviews [14]
- Clinical Trials [484]
- Methods Studies [2]
- Technology Assessments [33]
- Economic Evaluations [15]

There are 23 results out of 6076 records for: "hyperbaric oxygen" in Title, Abstract or Keywords in Cochrane Database of Systematic Reviews

**View:** 1-23

<table>
<thead>
<tr>
<th>Record Information</th>
<th>Issue</th>
<th>Restrict to</th>
<th>Sort by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperbaric oxygen for carbon monoxide poisoning</td>
<td>Current</td>
<td>Reviews</td>
<td>Record Title</td>
<td>January 2009</td>
</tr>
<tr>
<td>David N Juurlink, Nick Buckley, Matthew B Stanbrook, Geoff Isbister, Michael H Bennett, Michael McGugan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperbaric oxygen as an adjuvant treatment for malignant otitis externa</td>
<td>Current</td>
<td>Reviews</td>
<td>Record Title</td>
<td>April 2009</td>
</tr>
<tr>
<td>John S Phillips, Stephen EM Jones</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperbaric oxygen therapy for the adjunctive treatment of traumatic brain injury</td>
<td>Current</td>
<td>Reviews</td>
<td>Record Title</td>
<td>October 2009</td>
</tr>
<tr>
<td>Michael H Bennett, Barbara Trytko, Benjamin Jonker</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperbaric oxygen therapy for acute coronary syndrome</td>
<td>Current</td>
<td>Reviews</td>
<td>Record Title</td>
<td></td>
</tr>
</tbody>
</table>
Databases – TRIP

Order By: Date Relevance

1. Bariatric surgery for non-alcoholic steatohepatitis in obese patients
   - Cochrane Database of Systematic Reviews 2010
   - Use as CFD, Preview, Generate, Related

2. Bariatric Surgery in Women of Reproductive Age: Special Concerns for Pregnancy
   - Agency for Healthcare Research and Quality, Evidence-based Practice 2008
   - Use as CFD, Preview, Generate, Related

3. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation
   - McHHTA 2009
   - Use as CFD, Preview, Generate, Related

4. Bariatric surgery and pregnancy
   - American College of Obstetricians and Gynecologists 2009
   - Use as CFD, Preview, Generate, Related

5. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation

Filter Your Search

- Evidence Based Synopses: 10
- Systematic Reviews: 96
- Guidelines
  - Aus & NZ: 1
  - Canada: 2
  - UK: 11
  - USA: 8
  - Other: 0
- Clinical Q&A: 13
- Core primary research: 24
- Extended primary research: 1,353
Statistics

- Statistics on incidence and prevalence of specific conditions, population information

- Consult association websites for statistics on specific diseases not covered on major statistical websites

Statistics Canada
http://www.statscan.ca/

Public Health Agency of Canada (PHAC)
http://www.phac-aspc.gc.ca/

IHE Database of Online Health Statistics
http://www.ihe.ca/publications/health-db/
The Database of Online Health Statistics

The Database of Online Health Statistics provides quick and easy access to freely available web-based statistics generated by national and global agencies and research groups.

About the Database (40 KB)

Geography

- International
- Australasia
  - Australia
  - New Zealand
- Europe
  - Ireland
  - Norway
  - Sweden
  - United Kingdom
    - England
    - Scotland

Health Topic Areas

- Multiple Indicators
- Aboriginal Health
- Cancer
- Cardiovascular Disease
- Chronic Diseases
- Complementary and Alternative Medicine
- Diabetes
- Disabilities
- Elderly/Aging Health
- Guides and Pathfinders
- Health Economics/Healthcare
Infectious Diseases

Alberta
- Alberta Blood-borne Pathogens and Sexually Transmitted Infections 2008
- Community Acquired Methicillin Resistant Staphylococcus Aureus (CA MRSA) in Alberta
- Reporting of Haemolytic Uraemic Syndrome in the CIHI Hospital Inpatient System and the Alberta Notifiable Disease Registry
- Sociocultural factors affecting tuberculosis
- Summary Report: West Nile Virus in Alberta 2006
- Summary Report: West Nile Virus in Alberta 2007
- Tuberculosis in Alberta Surveillance Report 2000-2004
- West Nile Virus Surveillance in Alberta 2005

British Columbia
- BCCDC Statistics and Reports
Open Access Journals

- Journals where all content is freely available, no embargo period
- Often peer reviewed

PubMed Central [http://www.pubmedcentral.com](http://www.pubmedcentral.com)

Conferences/Congresses/Symposia

Manufacturer/Association websites

Input from experts/researchers

Online conference planners, conference reporting

http://www.medscape.com

http://www.doctorsreview.com/

http://www.biomedcentral.com/browse/abstracts/

Database records

for example: Biosis ($)

Internet search

(disease OR drug) AND (meeting* OR abstract* OR poster* OR conference* OR proceeding* OR poster*)
Additional Grey Literature Sources

Online catalogues

Amicus, NLM, British Library (BL), WorldCat

Theses

Theses Canada http://collectionscanada.ca/thesescanada/

Company directories and patents

Industry Canada databases: http://www.ic.gc.ca/

Patents database:
http://www.collectionscanada.gc.ca/innovations/023020-5000-e.html

Blogs/Discussion lists

CANMEDLIB

Expert Searching (MLA)
Managing Grey Literature Findings

Grey literature search results: M0016 HBOT

Table of contents:
- Background
- HTAs and Systematic Reviews/MAs
- CADTH
- Clinical Practice Guidelines
- Economic Studies
- Databases on the Internet
- Other

Notes:
- Publications limited to those dated 2005 or later.
- See the E-Publications folder for downloaded documents: T:\Project\HTIS_InProgress - Pending\M 00 16 HBOT\HBOT\searches/Resources//Publications

Background

UpToDate 2008 articles (downloaded)
- Hyperbaric Oxygen Therapy
- Carbon Monoxide Poisoning
- Smoke Inhalation

Note from Sara: Let me know if there are any UpToDate links given that you'd like to see me download.

ECRI Healthcare Product Comparison: Chambers, Hyperbaric HBOT April 2007 (downloaded) 25 p
Also downloaded comparison table from online database (Excel file).

HTAs and Systematic Reviews/MAs

Canadian

Indications for hyperbaric oxygen therapy: update
Report prepared by Guillaume Boureau, Khadija Mouad and Gilles Pineau, AEIMIS, Montreal, 2008
2008 05 rew FR.pdf [English summary (downloaded)] Ref ID 4444
ETB1282801 vol 4 no 6 2001 French report (downloaded) 2008 05 rew FR.pdf [French summary]

Hyperbaric Oxygen Therapy for the Treatment and Prevention of Radiotherapy and Other Radiation-Induced Injuries in Cancer Patients, CancerCare Ontario, August 2008 (downloaded)
http://www.cancercare.on.ca/forms/08.asp?pageid=00473 Ref ID 4447

Hyperbaric Oxygen Therapy for Non-Healing Ulcers in Diabetes Mellitus

Ontario Health Technology Assessment Series 2005
Volume 5, Number 11
Documents (report & summary, downloaded)
Ref ID: 4450

Related:
PATH Research Institute Field Evaluation
A prospective, double-blind randomized, controlled clinical trial comparing standard wound care with adjunctive Hyperbaric Oxygen Therapy (HBOT) to standard wound care only for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus
http://www.path-trials.org Project/?RefID:4451
Estimated study completion Spring 2010
Primary PATH investigator: Dr. Dana O'Reilly, MSc, PhD;
Phone: 403-523-7225 Ext. 5277;
Email: orelid@cmcoll.ca
Sample Size: 119
For further information please consult trial registration at www.clinicaltrials.gov

Saskatchewan Skin & Wound Care guidelines, Saskatchewan Health Quality Council 2008
http://www.hqc.ca/Portals/02/RT/CTC/CA/ Rh/hi/res/PHB/BH011LkLkS450R7zZk rCGSDFUZLWkh/xzu
214 pages.
Only one mention page 90. Excerpt:
Complementary Therapies
11.2. Hyperbaric oxygen may reduce ulcer size in non-diabetic, non-humanoid leg ulcers. Strength of Evidence = A

International

Hyperbaric oxygen for chronic wounds, Ref ID:1442
http://www.bndlr.jo.ac.uk/bandolierband/133/133-5.html

ECRI/2001 HBOT chronic wounds.pdf

Hyperbaric oxygen therapy (HBOT) for acute soft tissue injuries, ECRI Emerging Technology Evidence Reports 2006, (downloaded)

Hyperbaric Oxygen Therapy for Carbon Monoxide Intoxication, ECRI HTAIS Hotline, 2008, (downloaded) USE FOR BACKGROUND?

Hyperbaric Oxygen Therapy for Radiation Induced Osteonecrosis, ECRI HTAIS Hotline, 2008, (downloaded) USE FOR BACKGROUND?

Hyperbaric Oxygen Therapy for Burns Traumatic Injuries, ECRI HTAIS Hotline, 2008, (downloaded)
Managing Grey Literature Findings

Reference management software

Many can quickly save a webpage citation.

- RefWorks ($), Reference Manager ($), EndNote ($)
- Zotero (free Firefox extension)
- Mendeley (free, features managing PDFs)
Alerts and Awareness Tools

Limit searches by date range
- Google Advanced – last 24h, week, month(s), year

E-mail alerts & RSS feeds
- Set up alerts in databases such as Cochrane, CRD, TRIP
- RSS feeds: ClinicalTrials.gov, PubMed, MedScape, journals
Alerts & Awareness Tools

Webpage change detection services

- [http://watchthatpage.com/](http://watchthatpage.com/)
- [http://trackengine.com/](http://trackengine.com/)
Tips for your grey literature search!

- Have a well-developed strategy before you start
- Re-negotiate PICO & parameters as you search
- Keep it simple: paste title and link into a “good copy” document as you proceed

Grey literature searching is key for finding certain types of information and reducing publication bias
Giustini D. *Finding the hard to finds: searching for grey literature* [Internet]. University of British Columbia; 2010.  
http://www.slideshare.net/giustinid/finding-the-hard-to-finds-searching-for-grey-gray-literature-2010

http://www.ihe.ca/documents/HTA%20on%20the%20net%2010thedition_0.pdf

Document types in grey literature:
[http://www.greynet.org/greysourceindex/documenttypes.html](http://www.greynet.org/greysourceindex/documenttypes.html)

Grey source index:
[http://www.greynet.org/greysourceindex.html](http://www.greynet.org/greysourceindex.html)

Questions?